ReviewMini reviews in medicinal chemistry2026
New Therapeutic Options Against Clinically Relevant Proteases in Cancer Progression.
Review in Mini reviews in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Proteases are key regulators in cancer progression and metastasis, representing promising therapeutic targets. This review underscores the critical role of diverse proteases-encompassing cell surface ectoproteases, extracellular proteases, and intracellular proteases-in tumor biology, with a focus on the most significant and clinically relevant ones. Their overexpression in tumors reflects their importance in cancer development, invasion, and drug resistance. Emerging research has unveiled novel strategies to target proteases for cancer therapy, offering hope for improved treatment outcomes. However, challenges, such as selectivity, drug delivery, and toxicity remain significant hurdles to overcome. This article discusses current advancements, challenges, and future opportunities in targeting proteases for cancer therapy.
Indexed as
Identifiers
41787612What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.